Pharmacology of SCH00013: A novel Ca2+ sensitizer

Cardiovascular Drug Reviews

Volumn 19, Issue 4, 2001, Pages 345-368

  Endoh, Masao ^a   Sugawara, Hiromi ^b   Mineshima, Masahiro ^b  

^a YAMAGATA UNIVERSITY   (Japan)

^b ZENYAKU KOGYO CO LTD   (Japan)

Author keywords

Ca2+ sensitizer; Cardiotonic agent; Congestive heart failure; Positive inotropic effect; SCH00013

Indexed keywords

5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; 6 [1 [2 (4 CYANOPHENYL) 2 HYDROXYETHYL] 1,2,5,6 TETRAHYDRO 4 PYRIDYL] 4,5 DIHYDRO 3(2H) PYRIDAZINONE; ANTIARRHYTHMIC AGENT; CALCIUM SENSITIZER; CARBACHOL; CARDIOTONIC AGENT; CATECHOLAMINE; DIGITALIS; ISOPRENALINE; MILRINONE; PHOSPHODIESTERASE INHIBITOR; PIPERANOMETOZINE;

ACIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CHRONOTROPISM; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG TOXICITY; ENANTIOMER; GUINEA PIG; HUMAN; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVIEW; SIDE EFFECT; STEREOCHEMISTRY; STUNNED HEART MUSCLE;

EID: 0035725779     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2001.tb00075.x     Document Type: Review

References (72)

1. Calcium sensitization in perfused beating guinea pig heart by a positive inotropic agent MCI-154
2. Hemodynamic effects of MDL 17, 043, a new cardiotonic agent, in patients with congestive heart failure: Comparison with sodium nitroprusside
3. Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle
4. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea pig hearts
5. ++ as an inotropic mechanism
6. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium
7. Mechanisms of the contractile effects of levosimendan in the mammalian heart
8. Potassium channels and cardiac contraction
9. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
10. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril survival Study (CONSENSUS)
11. Effects of milrinone treatment in cardiomyopathic hamsters (CHF 147) with severe congestive heart failure
12. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart
13. The time course of changes in cyclic nucleotide levels during cholinergic inhibition of positive inotropic actions of isoprenaline and theophylline in the isolated canine ventricular myocardium
14. Dual inhibition of myocardial function through muscarinic and adenosine receptors in the mammalian heart
15. The effects of various drugs on the myocardial inotropic response
16. 2+ sensitization as mechanisms of action of physiological interventions and inotropic agents in intact myocardial cells
17. Effects of a new 1,3-thiazole derivative ZSY-39 on force of contraction and cyclic AMP content in canine ventricular muscle
18. Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG 212 Cl in canine ventricular myocardium
19. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle
20. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle
21. New cardiotonic agents: A search for digitalis substitute
22. Enantiomeric dissection of the effects of the inotropic agent, EMD 53998, in single cardiac myocytes
23. A new cardiotonic drug reduces the energy cost of active tension in cardiac muscle
24. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan
25. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation
26. Calcium-sensitizing inotropic agents in the treatment of heart failure: A critical view
27. ++ sensitizers impair cardiac relaxation in failing human myocardium
28. Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhythmias
29. Effects of EMD 57033 on contraction and relaxation in isolated rabbit hearts
30. ++ sensitizing action. 1st communication: Phosphodiesterase III inhibitory effect and class III antiarrhythmic effect in guinea pig heart
31. Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart
32. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: Comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine
33. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure
34. ++ sensitizer and a phosphodiesterase inhibitor on stunned myocardium
35. A novel thiadiazinone derivative fully reverses acidosis-induced depression of force in cardiac muscle by a calcium-sensitizing effect
36. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure
37. Altered myocardial force-frequency relation in human heart failure
38. Biventricular pacing in congestive heart failure: A post-ACC meeting perspective
39. SCH00013, a cardiotonic agent, improves survival of cardiomyopathic hamsters
40. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: Studies on isolated guinea pig cardiac muscles
41. Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? II. Protagonist's viewpoint
42. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
43. Effect of oral milrinone on mortality in severe chronic heart failure
44. The search for a digitalis substitute II milrinone (WIN 47203). Its action on the heart-lung preparation of the dog
45. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors
46. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure
47. Effect on contractility of skinned fibres from mammalian heart and smooth muscle by a new benzimidazole derivative, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)- pyridazinone
48. Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure
49. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit
50. Effect of inotropic stimulation on the negative force-frequency relationship in the failing human heart
51. Acute substantial benefit of inotropic therapy with amrinone on exercise hemodynamics and metabolism in severe congestive heart failure
52. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments
53. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
54. 2+, contraction, and potential in cardiac myocytes
55. 2+-sensitiser EMD 57033 in pigs at rest and during treadmill exercise
56. Ventricular energetics
57. ++ sensitizer with no chronotropic activity in mammalian cardiac muscle
58. ++ sensitizing action. 3rd communication: Stereoselectivity of the enantiomers in cardiovascular effects
59. Differential alteration of cardiotonic effects of EMD 57033 and beta-adrenoceptor agonists in volume-overload rabbit ventricular myocytes
60. Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart
61. Effects of intravenous amrinone on heart failure complicated by acute myocardial infarction: Comparative study with dopamine and dobutamine
62. Rate-dependent class III antiarrhythmic action, negative chronotropy, and positive inotropy of a novel Ik blocking drug, UK-68,798: Potent in guinea pig but no effect in rat myocardium
63. Class III antiarrhythmic action linked with positive inotropy: Effects of the d- and l-isomer of sotalol on isolated rat atria at threshold and suprathreshold stimulation
64. Class III antiarrhythmic action linked with positive inotropy: Acute electrophysiological and inotropic effects of amiodarone in vitro
65. The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure
66. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo
67. 2+ sensitizer Org-30029 reverses acidosis- and BDM-induced contractile depression in canine myocardium
68. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents
69. Xamoterol in severe heart failure
70. Interaction of potassium channel openers and blockers in canine atrial muscle
71. ++ sensitizing action. 2nd communication: In vivo cardiovascular effects and bioavailability in dogs
72. ++ sensitizing action. 4th communication: Influence on experimentally induced ventricular arrhythmia in dogs